Dube Michael P
SEC insider (Form 3/4/5 filer). CIK 0002019493. VP, Chief Accounting Officer at Intellia Therapeutics, Inc. (NTLA). 9 reported Form 4/5 transactions since Sep 2024; latest on Oct 2, 2026. Located in CAMBRIDGE, MA.
Companies Dube Michael P has filed insider reports for
- Intellia Therapeutics, Inc. (NTLA): Officer, VP, Chief Accounting Officer
Dube Michael P
CIK: 0002019493
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
Intellia Therapeutics, Inc.
Discretionary Trading P&L
Holdings
Transaction History (9 total)
- Oct 2, 2026NTLA
Intellia Therapeutics, Inc.
SaleDirect1.9K shares at avg. $12.43$23K - Jul 1, 2026NTLA
Intellia Therapeutics, Inc.
SaleDirect2.6K shares at avg. $16.78$44K - Mar 1, 2026NTLA
Intellia Therapeutics, Inc.
AwardDirect17.3K shares- - Jan 5, 2026NTLA
Intellia Therapeutics, Inc.
SaleDirect3K shares at avg. $9.21$28K - Oct 1, 2025NTLA
Intellia Therapeutics, Inc.
SaleDirect1.9K shares at avg. $17.38$33K - Jul 2, 2025NTLA
Intellia Therapeutics, Inc.
SaleDirect2.5K shares at avg. $9.95$25K - Mar 1, 2025NTLA
Intellia Therapeutics, Inc.
AwardDirect14K shares- - Jan 3, 2025NTLA
Intellia Therapeutics, Inc.
SaleDirect1.4K shares at avg. $12.18$17K - Oct 2, 2024NTLA
Intellia Therapeutics, Inc.
SaleDirect2K shares at avg. $19.01$38K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Oct 2, 2026 | NTLA Intellia Therapeutics, Inc. | Sale | 1,864 | $12.43 | $23,170 | Direct |
| Jul 1, 2026 | NTLA Intellia Therapeutics, Inc. | Sale | 2,641 | $16.78 | $44,316 | Direct |
| Mar 1, 2026 | NTLA Intellia Therapeutics, Inc. | Award | 17,250 | - | $0 | Direct |
| Jan 5, 2026 | NTLA Intellia Therapeutics, Inc. | Sale | 2,989 | $9.21 | $27,529 | Direct |
| Oct 1, 2025 | NTLA Intellia Therapeutics, Inc. | Sale | 1,871 | $17.38 | $32,518 | Direct |
| Jul 2, 2025 | NTLA Intellia Therapeutics, Inc. | Sale | 2,503 | $9.95 | $24,905 | Direct |
| Mar 1, 2025 | NTLA Intellia Therapeutics, Inc. | Award | 14,000 | - | - | Direct |
| Jan 3, 2025 | NTLA Intellia Therapeutics, Inc. | Sale | 1,372 | $12.18 | $16,711 | Direct |
| Oct 2, 2024 | NTLA Intellia Therapeutics, Inc. | Sale | 2,012 | $19.01 | $38,248 | Direct |
1-9 of 9 transactions